{"id":2227,"date":"2022-06-13T00:00:00","date_gmt":"2022-06-13T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2227"},"modified":"2022-06-13T00:00:00","modified_gmt":"2022-06-13T00:00:00","slug":"centogene%e3%81%a8agios%e3%81%af%e3%80%81%e5%b8%8c%e5%b0%91%e8%a1%80%e6%b6%b2%e7%96%be%e6%82%a3%e3%81%ae%e5%b0%8f%e5%85%90%e3%82%92%e6%b2%bb%e7%99%82%e3%81%99%e3%82%8b%e3%81%9f%e3%82%81%e3%81%ae","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/jp\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\/","title":{"rendered":"CENTOGENE\u3068Agios\u306f\u3001\u5e0c\u5c11\u8840\u6db2\u75be\u60a3\u306e\u5c0f\u5150\u3092\u6cbb\u7642\u3059\u308b\u305f\u3081\u306ePYRUKYND\u00ae\uff08\u30df\u30bf\u30d4\u30d0\u30c3\u30c8\uff09\u306e\u81e8\u5e8a\u958b\u767a\u306b\u304a\u3051\u308b\u63d0\u643a\u3092\u62e1\u5927"},"content":{"rendered":"<p class=\"h3\">18\u6b73\u672a\u6e80\u306e\u5c0f\u5150\u306b\u304a\u3051\u308b\u30d4\u30eb\u30d3\u30f3\u9178\u30ad\u30ca\u30fc\u30bc\uff08PK\uff09\u6b20\u640d\u75c7\u306e\u6839\u672c\u539f\u56e0\u3092\u6a19\u7684\u3068\u3059\u308b\u4e16\u754c\u521d\u306e\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u306b\u5171\u540c\u3067\u53d6\u308a\u7d44\u3093\u3067\u3044\u307e\u3059\u3002<br \/> &nbsp;<\/p>\n<ul>\n<li>ACTIVATE-kids\u304a\u3088\u3073ACTIVATE-kidsT\u306e\u7b2c3\u76f8\u8a66\u9a13\u3092\u542b\u3080\u3088\u3046\u306b\u5354\u529b\u95a2\u4fc2\u3092\u62e1\u5927<\/li>\n<li>CENTOGENE\u306e\u907a\u4f1d\u5b50\u691c\u67fb\u3068\u30d0\u30a4\u30aa\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u306f\u3001UGT1A1\u907a\u4f1d\u5b50\u3084PKLR\u907a\u4f1d\u5b50\u3092\u542b\u3080\u539f\u56e0\u3068\u306a\u308b\u5909\u7570\u3092\u7279\u5b9a\u3057\u3001\u6b63\u78ba\u306a\u8a3a\u65ad\u3092\u30b5\u30dd\u30fc\u30c8\u3057\u307e\u3059\u3002<\/li>\n<\/ul>\n<p> <strong>\u30de\u30b5\u30c1\u30e5\u30fc\u30bb\u30c3\u30c4\u5dde\u30b1\u30f3\u30d6\u30ea\u30c3\u30b8\u3001\u30c9\u30a4\u30c4\u30fb\u30ed\u30b9\u30c8\u30c3\u30af\u3001\u30d9\u30eb\u30ea\u30f3\u30012022\u5e746\u670813\u65e5\uff08GLOBE NEWSWIRE\uff09<\/strong> \u2013 \u5e0c\u5c11\u75be\u60a3\u304a\u3088\u3073\u795e\u7d4c\u5909\u6027\u75be\u60a3\u5411\u3051\u306e\u5546\u696d\u6bb5\u968e\u306e\u5fc5\u9808\u30d0\u30a4\u30aa\u30c7\u30fc\u30bf\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u30d1\u30fc\u30c8\u30ca\u30fc\u3067\u3042\u308bCentogene NV\uff08\u30ca\u30b9\u30c0\u30c3\u30af\uff1aCNTG\uff09\u306f\u672c\u65e5\u3001\u9577\u5e74\u306b\u308f\u305f\u308bPYRUKYND\u3068\u306e\u63d0\u643a\u3092\u62e1\u5927\u3057\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002<sup>\u00ae<\/sup> \uff08\u30df\u30bf\u30d4\u30d0\u30c3\u30c8\uff09\u306f\u3001\u7d30\u80de\u4ee3\u8b1d\u5206\u91ce\u306e\u30ea\u30fc\u30c0\u30fc\u3067\u3042\u308a\u3001\u907a\u4f1d\u7684\u306b\u5b9a\u7fa9\u3055\u308c\u305f\u75be\u60a3\u306b\u5bfe\u3059\u308b\u6cbb\u7642\u6cd5\u3092\u958b\u62d3\u3057\u3066\u3044\u308bAgios Pharmaceuticals, Inc.\uff08NASDAQ\uff1aAGIO\uff09\u3068\u63d0\u643a\u3057\u3066\u3044\u307e\u3059\u3002.<\/p>\n<p>\u30a2\u30ae\u30aa\u30b9\u306e\u30d4\u30eb\u30ad\u30f3\u30c9<sup>\u00ae<\/sup> PYRUKYND\u306f\u3001\u30d4\u30eb\u30d3\u30f3\u9178\u30ad\u30ca\u30fc\u30bc\uff08PK\uff09\u9175\u7d20\u306e\u9078\u629e\u7684\u4f4e\u5206\u5b50\u6d3b\u6027\u5316\u5264\u3067\u3042\u308a\u3001\u30af\u30e9\u30b9\u521d\u306e\u85ac\u5264\u3067\u3059\u30022022\u5e742\u6708\u3001Agios\u793e\u306f\u7c73\u56fd\u98df\u54c1\u533b\u85ac\u54c1\u5c40\uff08FDA\uff09\u304b\u3089PYRUKYND\u306e\u627f\u8a8d\u3092\u53d6\u5f97\u3057\u307e\u3057\u305f\u3002<sup>\u00ae<\/sup> PK\u6b20\u640d\u75c7\u306e\u6210\u4eba\u306b\u304a\u3051\u308b\u6eb6\u8840\u6027\u8ca7\u8840\u306e\u6cbb\u7642\u85ac\u3067\u3042\u308a\u3001\u3053\u306e\u5e0c\u5c11\u8840\u6db2\u75be\u60a3\u306b\u5bfe\u3059\u308b\u6700\u521d\u3067\u552f\u4e00\u306e\u627f\u8a8d\u3055\u308c\u305f\u75be\u60a3\u4fee\u98fe\u7642\u6cd5\u3067\u3042\u308b\u30022015\u5e74\u4ee5\u6765\u3001CENTOGENE\u306fPYRUKYND\u306e\u81e8\u5e8a\u958b\u767a\u306e\u305f\u3081\u306bAgios\u306b\u907a\u4f1d\u5b50\u691c\u67fb\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3057\u3066\u304d\u305f\u3002<sup>\u00ae<\/sup>.<\/p>\n<p>\u4eca\u56de\u306e\u5951\u7d04\u62e1\u5927\u306b\u3088\u308a\u3001CENTOGENE\u306f\u3001Agios\u304c\u5b9f\u65bd\u3059\u308b2\u3064\u306e\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u7b2c3\u76f8\u81e8\u5e8a\u8a66\u9a13\u3001ACTIVATE-kids\u304a\u3088\u3073ACTIVATE-kidsT\u306b\u5bfe\u3057\u3001\u4e2d\u592e\u96c6\u4e2d\u578b\u306e\u691c\u67fb\u30b5\u30dd\u30fc\u30c8\u3092\u63d0\u4f9b\u3059\u308b\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002\u3053\u308c\u3089\u306e\u8a66\u9a13\u306f\u30011\u6b73\u304b\u308917\u6b73\u307e\u3067\u306ePK\u6b20\u640d\u75c7\u306e\u5c0f\u5150\u306b\u304a\u3051\u308b\u30df\u30bf\u30d4\u30d0\u30c3\u30c8\u306e\u6709\u52b9\u6027\u3068\u5b89\u5168\u6027\u3092\u8a55\u4fa1\u3059\u308b\u305f\u3081\u306b\u5b9f\u65bd\u3055\u308c\u3066\u3044\u307e\u3059\u3002CENTOGENE\u306f\u3001\u5f15\u304d\u7d9a\u304d\u3001\u8a66\u9a13\u53c2\u52a0\u8005\u306b\u304a\u3051\u308bUGT1A1\u907a\u4f1d\u5b50\u3084PKLR\u907a\u4f1d\u5b50\u306a\u3069\u306e\u539f\u56e0\u3068\u306a\u308b\u5909\u7570\u3092\u7279\u5b9a\u3059\u308b\u305f\u3081\u306e\u907a\u4f1d\u5b50\u691c\u67fb\u3092\u63d0\u4f9b\u3057\u307e\u3059\u3002\u7b2c3\u76f8ACTIVATE-kids\u304a\u3088\u3073ACTIVATE-kidsT\u8a66\u9a13\u306e\u76ee\u7684\u306f\u3001PYRUKYND\u306e\u6709\u52b9\u6027\u3092\u691c\u8a3c\u3059\u308b\u3053\u3068\u3067\u3059\u3002<sup>\u00ae<\/sup> PK\u6b20\u640d\u75c7\u306e\u5c0f\u5150\u60a3\u8005\u306e\u3046\u3061\u3001\u5b9a\u671f\u7684\u306a\u8f38\u8840\u3092\u53d7\u3051\u3066\u3044\u306a\u3044\u60a3\u8005\u3068\u3001\u5b9a\u671f\u7684\u306b\u8f38\u8840\u3092\u53d7\u3051\u3066\u3044\u308b\u60a3\u8005\u3092\u305d\u308c\u305e\u308c\u5bfe\u8c61\u3068\u3059\u308b\u3002\u30a2\u30ae\u30aa\u30b9\u306f\u3053\u308c\u3089\u306e\u30d7\u30ed\u30b0\u30e9\u30e0\u306e\u8abf\u6574\u3068\u8cbb\u7528\u8ca0\u62c5\u3092\u884c\u3046\u3002\u305d\u306e\u4ed6\u306e\u8ca1\u52d9\u8a73\u7d30\u306f\u660e\u3089\u304b\u306b\u3055\u308c\u3066\u3044\u306a\u3044\u3002.<\/p>\n<p>\u201c\u300cAgios\u793e\u3068\u306e\u5354\u529b\u95a2\u4fc2\u306e\u6210\u529f\u306b\u3088\u308a\u3001\u3053\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30a4\u30f3\u30af\u30e9\u30b9\u306ePK\u6d3b\u6027\u5316\u5264\u304c\u3001\u30d4\u30eb\u30d3\u30f3\u9178\u30ad\u30ca\u30fc\u30bc\u6b20\u640d\u75c7\u306e\u5c0f\u5150\u60a3\u8005\u306b\u5bfe\u3059\u308b\u6cbb\u7642\u85ac\u3068\u3057\u3066\u3001\u76ee\u899a\u307e\u3057\u3044\u81e8\u5e8a\u7684\u9032\u6b69\u3092\u9042\u3052\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u75be\u60a3\u306f\u3001\u6cbb\u7642\u9078\u629e\u80a2\u3092\u7dca\u6025\u306b\u5fc5\u8981\u3068\u3057\u3066\u3044\u308b\u3001\u5341\u5206\u306a\u533b\u7642\u30b5\u30fc\u30d3\u30b9\u3092\u53d7\u3051\u3066\u3044\u306a\u3044\u60a3\u8005\u5c64\u3067\u3059\u3002\u4eca\u56de\u306e\u63d0\u643a\u62e1\u5927\u306f\u3001\u4e16\u754c\u4e2d\u306e\u60a3\u8005\u306e\u5065\u5eb7\u72b6\u614b\u306b\u5f71\u97ff\u3092\u4e0e\u3048\u308b\u3053\u3068\u304c\u3067\u304d\u308b\u3001\u9769\u65b0\u7684\u306a\u6cbb\u7642\u9078\u629e\u80a2\u306e\u958b\u767a\u3092\u652f\u63f4\u3067\u304d\u308b\u5f53\u793e\u306e\u80fd\u529b\u3092\u88cf\u4ed8\u3051\u308b\u3082\u306e\u3067\u3059\u300d\u3068\u3001CENTOGENE\u306eCEO\u3067\u3042\u308b\u30ad\u30e0\u30fb\u30b9\u30c8\u30e9\u30c3\u30c8\u30f3\u6c0f\u306f\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300c\u5f53\u793e\u306f\u3001\u5e0c\u5c11\u75be\u60a3\u304a\u3088\u3073\u795e\u7d4c\u5909\u6027\u75be\u60a3\u306b\u95a2\u3059\u308b\u4e16\u754c\u6700\u5927\u306e\u5b9f\u4e16\u754c\u30c7\u30fc\u30bf\u30ea\u30dd\u30b8\u30c8\u30ea\u3067\u3042\u308bCENTOGENE\u30d0\u30a4\u30aa\u30c7\u30fc\u30bf\u30d0\u30f3\u30af\u3092\u6d3b\u7528\u3057\u305f\u3001\u6bd4\u985e\u306e\u306a\u3044\u8a3a\u65ad\u30b5\u30fc\u30d3\u30b9\u3068\u77e5\u898b\u3092\u63d0\u4f9b\u3059\u308b\u3053\u3068\u3067\u3001\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u304a\u3088\u3073\u88fd\u85ac\u30d1\u30fc\u30c8\u30ca\u30fc\u306e\u81e8\u5e8a\u958b\u767a\u306b\u304a\u3044\u3066\u975e\u5e38\u306b\u91cd\u8981\u306a\u30d0\u30a4\u30aa\u30c7\u30fc\u30bf\u3092\u63d0\u4f9b\u3057\u307e\u3059\u3002\u300d\u201d<\/p>\n<p>\u30a2\u30ae\u30aa\u30b9\u306e\u6700\u9ad8\u533b\u7642\u8cac\u4efb\u8005\u3067\u3042\u308b\u30b5\u30e9\u30fb\u30b2\u30e5\u30a8\u30f3\u30b9\u533b\u5e2b\uff08\u533b\u5b66\u535a\u58eb\uff09\u306f\u3001\u300c\u5c0f\u5150\u30d4\u30eb\u30d3\u30f3\u9178\u30ad\u30ca\u30fc\u30bc\u6b20\u640d\u75c7\u306b\u95a2\u3059\u308b\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u4e3b\u8981\u81e8\u5e8a\u8a66\u9a13\u3092\u9032\u3081\u308b\u306b\u3042\u305f\u308a\u3001\u30bb\u30f3\u30c8\u30b8\u30fc\u30f3\u793e\u3068\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u3092\u62e1\u5927\u3057\u3001\u3053\u308c\u3089\u306e\u60a3\u8005\u306b\u5bfe\u3059\u308b\u521d\u306e\u6709\u671b\u306a\u6cbb\u7642\u6cd5\u3092\u3001\u5b50\u3069\u3082\u305f\u3061\u3068\u305d\u306e\u5bb6\u65cf\u306e\u751f\u6d3b\u306b\u5927\u304d\u306a\u5f71\u97ff\u3092\u4e0e\u3048\u308b\u4e00\u6b69\u624b\u524d\u306b\u8fd1\u3065\u3051\u308b\u3053\u3068\u304c\u3067\u304d\u3001\u5927\u5909\u5b09\u3057\u304f\u601d\u3044\u307e\u3059\u3002\u30a2\u30ae\u30aa\u30b9\u3067\u306f\u3001\u512a\u308c\u305f\u79d1\u5b66\u7814\u7a76\u306b\u306f\u4e16\u754c\u30ec\u30d9\u30eb\u306e\u5354\u529b\u304c\u4e0d\u53ef\u6b20\u3067\u3042\u308b\u3053\u3068\u3092\u7406\u89e3\u3057\u3066\u3044\u307e\u3059\u3002\u81e8\u5e8a\u8a66\u9a13\u306e\u52a0\u901f\u3068\u52b9\u7387\u5316\u306f\u3001\u65b0\u305f\u306a\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3092\u53ef\u80fd\u306a\u9650\u308a\u52b9\u7387\u7684\u306b\u60a3\u8005\u306b\u5c4a\u3051\u308b\u305f\u3081\u306b\u4e0d\u53ef\u6b20\u3067\u3042\u308a\u3001\u30bb\u30f3\u30c8\u30b8\u30fc\u30f3\u793e\u306e\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306f\u3001\u3053\u306e\u30d7\u30ed\u30b8\u30a7\u30af\u30c8\u306b\u3068\u3063\u3066\u6700\u9069\u306a\u30d1\u30fc\u30c8\u30ca\u30fc\u3067\u3059\u300d\u3068\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u201c<\/p>\n<p>\u3053\u306e\u63d0\u643a\u306b\u304a\u3044\u3066\u3001CENTOGENE\u72ec\u81ea\u306eCentoCard\u306f<sup>\u00ae<\/sup> \u4e7e\u71e5\u8840\u6db2\u30b9\u30dd\u30c3\u30c8\u6280\u8853\u306f\u3001\u4e2d\u592e\u8a3a\u65ad\u691c\u67fb\u306e\u305f\u3081\u306e\u5bb9\u6613\u306a\u7269\u6d41\u3092\u5b9f\u73fe\u3057\u307e\u3059\u3002\u3053\u306e\u63d0\u643a\u306b\u304a\u3051\u308b\u4e3b\u8981\u306a\u8cc7\u7523\u306b\u306f\u3001CENTOGENE\u30d0\u30a4\u30aa\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u300115\u5e74\u4ee5\u4e0a\u306b\u308f\u305f\u308b\u7d4c\u9a13\u306b\u57fa\u3065\u3044\u305f\u8a3a\u65ad\u5c02\u9580\u77e5\u8b58\u3001\u305d\u3057\u3066\u73fe\u5728\u5e02\u5834\u306b\u51fa\u56de\u3063\u3066\u3044\u308b\u5546\u7528\u30de\u30eb\u30c1\u30aa\u30df\u30af\u30b9\u88fd\u54c1\u3078\u306e\u30a2\u30af\u30bb\u30b9\u3092\u5148\u99c6\u3051\u308b\u540c\u793e\u306e\u30de\u30eb\u30c1\u30aa\u30df\u30af\u30b9\u30d9\u30fc\u30b9\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u304c\u542b\u307e\u308c\u307e\u3059\u3002.<\/p>\n<p>2015\u5e74\u3001CENTOGENE\u306fAgios\u793e\u3068\u3001Agios\u793e\u306ePK\u6b20\u640d\u75c7\u81e8\u5e8a\u30d7\u30ed\u30b0\u30e9\u30e0\u3092\u652f\u63f4\u3059\u308b\u5951\u7d04\u3092\u7de0\u7d50\u3057\u307e\u3057\u305f\u3002\u6628\u5e74\u3001\u3053\u306e\u5951\u7d04\u306f\u62e1\u5927\u3055\u308c\u3001\u30b5\u30e9\u30bb\u30df\u30a2\u3068\u938c\u72b6\u8d64\u8840\u7403\u75c7\u306b\u304a\u3051\u308b\u8ffd\u52a0\u306e\u6cbb\u9a13\u652f\u63f4\u306b\u91cd\u70b9\u3092\u7f6e\u304f\u3088\u3046\u306b\u306a\u308a\u307e\u3057\u305f\u3002.<\/p>\n<h3>PYRUKYND\u00ae\uff08\u30df\u30bf\u30d4\u30d0\u30c3\u30c8\uff09\u306b\u3064\u3044\u3066<\/h3>\n<p>\u30d4\u30eb\u30ad\u30f3\u30c9<sup>\u00ae<\/sup> PYRUKYND\u306f\u3001\u30d4\u30eb\u30d3\u30f3\u9178\u30ad\u30ca\u30fc\u30bc\uff08PK\uff09\u6b20\u640d\u75c7\u306e\u6210\u4eba\u306b\u304a\u3051\u308b\u6eb6\u8840\u6027\u8ca7\u8840\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066\u9069\u5fdc\u3055\u308c\u308b\u30d4\u30eb\u30d3\u30f3\u9178\u30ad\u30ca\u30fc\u30bc\u6d3b\u6027\u5316\u5264\u3067\u3059\u30022022\u5e742\u6708\u3001Agios\u793e\u306f\u7c73\u56fd\u98df\u54c1\u533b\u85ac\u54c1\u5c40\uff08FDA\uff09\u304b\u3089PYRUKYND\u306e\u627f\u8a8d\u3092\u53d6\u5f97\u3057\u307e\u3057\u305f\u3002<sup>\u00ae<\/sup> \u672c\u5264\u306f\u3001PK\u6b20\u640d\u75c7\u306e\u6210\u4eba\u306b\u304a\u3051\u308b\u6eb6\u8840\u6027\u8ca7\u8840\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066\u627f\u8a8d\u3055\u308c\u3066\u304a\u308a\u3001\u3053\u306e\u5e0c\u5c11\u306a\u8840\u6db2\u75be\u60a3\u306e\u6210\u4eba\u306b\u5bfe\u3059\u308b\u6700\u521d\u3067\u552f\u4e00\u306e\u75be\u60a3\u4fee\u98fe\u7642\u6cd5\u85ac\u3067\u3059\u3002\u307e\u305f\u3001\u6b27\u5dde\u533b\u85ac\u54c1\u5e81\uff08EMA\uff09\u304b\u3089\u3001\u51fa\u751f\u304b\u30891\u6b73\u672a\u6e80\u306e\u5c0f\u5150\u306b\u304a\u3051\u308bPK\u6b20\u640d\u75c7\u306e\u6cbb\u7642\u306b\u95a2\u3059\u308b\u5c0f\u5150\u6cbb\u9a13\u8a08\u753b\uff08PIP\uff09\u306b\u57fa\u3065\u304d\u3001\u627f\u8a8d\u514d\u9664\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002.<\/p>\n<h3>PK\u6b20\u4e4f\u75c7\u306b\u3064\u3044\u3066<\/h3>\n<p>\u30d4\u30eb\u30d3\u30f3\u9178\u30ad\u30ca\u30fc\u30bc\uff08PK\uff09\u6b20\u640d\u75c7\u306f\u3001\u6162\u6027\u6eb6\u8840\u6027\u8ca7\u8840\uff08\u8d64\u8840\u7403\u306e\u7834\u58ca\u304c\u52a0\u901f\u3059\u308b\u72b6\u614b\uff09\u3068\u3057\u3066\u73fe\u308c\u308b\u307e\u308c\u306a\u907a\u4f1d\u6027\u75be\u60a3\u3067\u3059\u3002PKLR\u907a\u4f1d\u5b50\u306e\u907a\u4f1d\u6027\u5909\u7570\u306f\u3001PKR\u9175\u7d20\u6d3b\u6027\u306e\u4f4e\u4e0b\u3001\u30a2\u30c7\u30ce\u30b7\u30f3\u4e09\u30ea\u30f3\u9178\uff08ATP\uff09\u30ec\u30d9\u30eb\u306e\u4f4e\u4e0b\u3001\u304a\u3088\u30732,3-DPG\uff082,3-\u30b8\u30db\u30b9\u30db\u30b0\u30ea\u30bb\u30ea\u30f3\u9178\uff09\u306a\u3069\u306e\u4e0a\u6d41\u4ee3\u8b1d\u7523\u7269\u306e\u84c4\u7a4d\u306b\u3088\u3063\u3066\u793a\u3055\u308c\u308b\u3088\u3046\u306b\u3001\u8d64\u8840\u7403\u5185\u306e\u7d30\u80de\u30a8\u30cd\u30eb\u30ae\u30fc\u306e\u6b20\u4e4f\u3092\u5f15\u304d\u8d77\u3053\u3057\u307e\u3059\u3002.<\/p>\n<p>PK\u6b20\u640d\u75c7\u306f\u3001\u7c73\u56fd\u304a\u3088\u3073EU5\u8af8\u56fd\u306b\u304a\u3044\u3066\u7d043,000\u4eba\u304b\u30898,000\u4eba\u306b\u5f71\u97ff\u3092\u4e0e\u3048\u3066\u3044\u308b\u3002PK\u6b20\u640d\u75c7\u306f\u3001\u80ba\u9ad8\u8840\u5727\u75c7\u3001\u9ac4\u5916\u9020\u8840\u3001\u9aa8\u7c97\u9b06\u75c7\u306a\u3069\u306e\u91cd\u7be4\u306a\u5408\u4f75\u75c7\u3092\u5f15\u304d\u8d77\u3053\u3059\u53ef\u80fd\u6027\u304c\u3042\u308b\u3002.<\/p>\n<p>ACTIVATE-kids\u304a\u3088\u3073ACTIVATE-kidsT\u81e8\u5e8a\u8a66\u9a13\u306e\u8a73\u7d30\u306b\u3064\u3044\u3066\u306f\u3001\u4ee5\u4e0b\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002 <a href=\"https:\/\/www.agios.com\/patients-partners\/patients-caregivers\/clinical-trials\/ \" target=\"_blank\" title=\"Agios ACTIVATE-kids\u304a\u3088\u3073ACTIVATE-kidsT\u81e8\u5e8a\u8a66\u9a13\">https:\/\/www.agios.com\/patients-partners\/patients-caregivers\/clinical-trials\/ <\/a><\/p>\n<h3>\u30a2\u30ae\u30aa\u30b9\u306b\u3064\u3044\u3066<\/h3>\n<p>Agios\u306f\u3001\u3064\u306a\u304c\u308a\u3092\u539f\u52d5\u529b\u3068\u3059\u308b\u30d0\u30a4\u30aa\u533b\u85ac\u54c1\u4f01\u696d\u3067\u3059\u3002Agios\u30c1\u30fc\u30e0\u306f\u3001\u60a3\u8005\u30b3\u30df\u30e5\u30cb\u30c6\u30a3\u3001\u533b\u7642\u5f93\u4e8b\u8005\u3001\u30d1\u30fc\u30c8\u30ca\u30fc\u3001\u540c\u50da\u3068\u306e\u5f37\u56fa\u306a\u95a2\u4fc2\u3092\u7bc9\u304d\u3001\u907a\u4f1d\u7684\u306b\u5b9a\u7fa9\u3055\u308c\u305f\u75be\u60a3\u306b\u5bfe\u3059\u308b\u6cbb\u7642\u6cd5\u306e\u767a\u898b\u3001\u958b\u767a\u3001\u63d0\u4f9b\u306b\u53d6\u308a\u7d44\u3093\u3067\u3044\u307e\u3059\u3002\u7c73\u56fd\u3067\u306f\u3001Agios\u306f\u3001\u30d4\u30eb\u30d3\u30f3\u9178\u30ad\u30ca\u30fc\u30bc\uff08PK\uff09\u6b20\u640d\u75c7\u306e\u6210\u4eba\u60a3\u8005\u5411\u3051\u306b\u3001\u30d5\u30a1\u30fc\u30b9\u30c8\u30a4\u30f3\u30af\u30e9\u30b9\u306ePK\u6d3b\u6027\u5316\u5264\u3092\u8ca9\u58f2\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u308c\u306f\u3001\u3053\u306e\u5e0c\u5c11\u3067\u751f\u6daf\u306b\u308f\u305f\u308b\u8870\u5f31\u6027\u6eb6\u8840\u6027\u8ca7\u8840\u306b\u5bfe\u3059\u308b\u521d\u306e\u75be\u60a3\u4fee\u98fe\u7642\u6cd5\u3067\u3059\u3002\u7d30\u80de\u4ee3\u8b1d\u5206\u91ce\u306b\u304a\u3051\u308b\u540c\u793e\u306e\u30ea\u30fc\u30c0\u30fc\u30b7\u30c3\u30d7\u3092\u57fa\u76e4\u3068\u3057\u3066\u3001Agios\u306f\u3001\u03b1-\u30b5\u30e9\u30bb\u30df\u30a2\u3001\u03b2-\u30b5\u30e9\u30bb\u30df\u30a2\u3001\u938c\u72b6\u8d64\u8840\u7403\u75c7\u3001\u5c0f\u5150PK\u6b20\u640d\u75c7\u3001MDS\u95a2\u9023\u8ca7\u8840\u306b\u304a\u3044\u3066\u3001\u9032\u884c\u4e2d\u304a\u3088\u3073\u8a08\u753b\u4e2d\u306e\u30d7\u30ed\u30b0\u30e9\u30e0\u3092\u542b\u3080\u3001\u5f37\u529b\u306a\u81e8\u5e8a\u30d1\u30a4\u30d7\u30e9\u30a4\u30f3\u306e\u6cbb\u9a13\u85ac\u306e\u958b\u767a\u3092\u9032\u3081\u3066\u3044\u307e\u3059\u3002\u81e8\u5e8a\u30d1\u30a4\u30d7\u30e9\u30a4\u30f3\u306b\u52a0\u3048\u3001Agios\u306f\u8907\u6570\u306e\u6cbb\u9a13\u85ac\u3092\u524d\u81e8\u5e8a\u958b\u767a\u6bb5\u968e\u306b\u6301\u3061\u3001\u7d30\u80de\u4ee3\u8b1d\u3068\u907a\u4f1d\u5b66\u306b\u304a\u3044\u3066\u6bd4\u985e\u306e\u306a\u3044\u5c02\u9580\u77e5\u8b58\u3092\u6301\u3064\u696d\u754c\u3092\u30ea\u30fc\u30c9\u3059\u308b\u7814\u7a76\u30c1\u30fc\u30e0\u3092\u64c1\u3057\u3066\u3044\u307e\u3059\u3002\u8a73\u7d30\u306b\u3064\u3044\u3066\u306f\u3001\u540c\u793e\u306e\u30a6\u30a7\u30d6\u30b5\u30a4\u30c8\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002 <a href=\"https:\/\/www.agios.com\/\" target=\"_blank\" title=\"\u30a2\u30ae\u30aa\u30b9\">https:\/\/www.agios.com\/<\/a><\/p>\n<h3>CENTOGENE\u306b\u3064\u3044\u3066<\/h3>\n<p>CENTOGENE\u306f\u3001\u5e0c\u5c11\u75be\u60a3\u306e\u8a3a\u65ad\u3068\u7814\u7a76\u306b\u53d6\u308a\u7d44\u3093\u3067\u304a\u308a\u3001\u5b9f\u4e16\u754c\u306e\u81e8\u5e8a\u30c7\u30fc\u30bf\u3001\u907a\u4f1d\u5b50\u30c7\u30fc\u30bf\u3001\u30de\u30eb\u30c1\u30aa\u30df\u30af\u30b9\u30c7\u30fc\u30bf\u3092\u6d3b\u7528\u3057\u3066\u3001\u5e0c\u5c11\u75be\u60a3\u306e\u8a3a\u65ad\u3001\u7406\u89e3\u3001\u6cbb\u7642\u3092\u884c\u3063\u3066\u3044\u307e\u3059\u3002\u5f53\u793e\u306e\u76ee\u6a19\u306f\u3001\u8c4a\u5bcc\u306a\u5e0c\u5c11\u75be\u60a3\u306b\u95a2\u3059\u308b\u77e5\u8b58\u3068\u30c7\u30fc\u30bf\u3092\u6d3b\u7528\u3057\u3001\u6cbb\u7642\u65b9\u91dd\u306e\u6c7a\u5b9a\u306b\u5408\u7406\u6027\u3092\u3082\u305f\u3089\u3057\u3001\u65b0\u305f\u306a\u30aa\u30fc\u30d5\u30a1\u30f3\u30c9\u30e9\u30c3\u30b0\u306e\u958b\u767a\u3092\u52a0\u901f\u3059\u308b\u3053\u3068\u3067\u3059\u3002CENTOGENE\u306f\u3001120\u304b\u56fd\u4ee5\u4e0a\u300165\u4e07\u4eba\u3092\u8d85\u3048\u308b\u500b\u4eba\u306e\u5b9f\u4e16\u754c\u30c7\u30fc\u30bf\u30ea\u30dd\u30b8\u30c8\u30ea\u306b\u57fa\u3065\u3044\u305f\u3001\u72ec\u81ea\u306e\u30b0\u30ed\u30fc\u30d0\u30eb\u5e0c\u5c11\u75be\u60a3\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.<\/p>\n<p>\u5f53\u793e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306b\u306f\u3001\u4e16\u754c\u4e2d\u306e\u4eba\u53e3\u3092\u53cd\u6620\u3057\u305f\u75ab\u5b66\u7684\u3001\u8868\u73fe\u578b\u7684\u3001\u304a\u3088\u3073\u907a\u4f1d\u5b50\u30c7\u30fc\u30bf\u306b\u52a0\u3048\u3001\u60a3\u8005\u306e\u8840\u6db2\u30b5\u30f3\u30d7\u30eb\u3068\u7d30\u80de\u57f9\u990a\u306e\u30d0\u30a4\u30aa\u30d0\u30f3\u30af\u304c\u542b\u307e\u308c\u3066\u3044\u307e\u3059\u3002CENTOGENE\u306f\u3001\u3053\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u304c\u5e0c\u5c11\u907a\u4f1d\u6027\u75be\u60a3\u306e\u7406\u89e3\u3092\u6df1\u3081\u308b\u305f\u3081\u306b\u3001\u591a\u6bb5\u968e\u30c7\u30fc\u30bf\u306e\u5305\u62ec\u7684\u306a\u5206\u6790\u306b\u7279\u5316\u3057\u305f\u552f\u4e00\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3042\u308b\u3068\u78ba\u4fe1\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u308c\u306b\u3088\u308a\u3001\u60a3\u8005\u3068\u305d\u306e\u57fa\u790e\u75be\u60a3\u3092\u3088\u308a\u9069\u5207\u306b\u7279\u5b9a\u3057\u3001\u5c64\u5225\u5316\u3059\u308b\u3053\u3068\u304c\u53ef\u80fd\u306b\u306a\u308a\u3001\u5e0c\u5c11\u75be\u60a3\u6cbb\u7642\u85ac\u306e\u767a\u898b\u3001\u958b\u767a\u3001\u304a\u3088\u3073\u30a2\u30af\u30bb\u30b9\u3092\u4fc3\u9032\u30fb\u52a0\u901f\u3055\u305b\u308b\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u30022021\u5e7412\u670831\u65e5\u73fe\u5728\u3001\u5f53\u793e\u306f30\u793e\u4ee5\u4e0a\u306e\u88fd\u85ac\u30d1\u30fc\u30c8\u30ca\u30fc\u3068\u63d0\u643a\u3057\u3066\u3044\u307e\u3059\u3002.<\/p>\n<p>\u30d5\u30a9\u30ed\u30fc\u3057\u3066\u304f\u3060\u3055\u3044 <a href=\"https:\/\/de.linkedin.com\/company\/centogene\" target=\"_blank\" title=\"LinkedIn\">LinkedIn<\/a>.&nbsp;<\/p>\n<h3>\u5c06\u6765\u306e\u898b\u901a\u3057\u306b\u95a2\u3059\u308b\u8a18\u8ff0<\/h3>\n<p>\u672c\u30d7\u30ec\u30b9\u30ea\u30ea\u30fc\u30b9\u306b\u306f\u3001\u7c73\u56fd\u9023\u90a6\u8a3c\u5238\u6cd5\u306b\u304a\u3051\u308b\u300c\u5c06\u6765\u4e88\u6e2c\u306b\u95a2\u3059\u308b\u8a18\u8ff0\u300d\u304c\u542b\u307e\u308c\u3066\u3044\u307e\u3059\u3002\u672c\u30d7\u30ec\u30b9\u30ea\u30ea\u30fc\u30b9\u306b\u542b\u307e\u308c\u308b\u8a18\u8ff0\u306e\u3046\u3061\u3001\u660e\u3089\u304b\u306b\u904e\u53bb\u306e\u4e8b\u5b9f\u3067\u306f\u306a\u3044\u3082\u306e\u306f\u5c06\u6765\u4e88\u6e2c\u306b\u95a2\u3059\u308b\u8a18\u8ff0\u3067\u3042\u308a\u3001\u300c\u4e88\u60f3\u3059\u308b\u300d\u300c\u4fe1\u3058\u308b\u300d\u300c\u7d99\u7d9a\u3059\u308b\u300d\u300c\u671f\u5f85\u3059\u308b\u300d\u300c\u898b\u7a4d\u3082\u308b\u300d\u300c\u610f\u56f3\u3059\u308b\u300d\u300c\u4e88\u6e2c\u3059\u308b\u300d\u306a\u3069\u306e\u8a9e\u53e5\u3001\u304a\u3088\u3073\u300c\uff5e\u3060\u308d\u3046\u300d\u300c\uff5e\u3067\u3042\u308d\u3046\u300d\u300c\uff5e\u3059\u3079\u304d\u3067\u3042\u308b\u300d\u300c\uff5e\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u300d\u300c\uff5e\u3059\u308b\u304b\u3082\u3057\u308c\u306a\u3044\u300d\u300c\uff5e\u3067\u304d\u308b\u300d\u300c\uff5e\u3059\u308b\u304b\u3082\u3057\u308c\u306a\u3044\u300d\u306a\u3069\u306e\u672a\u6765\u5f62\u307e\u305f\u306f\u6761\u4ef6\u4ed8\u304d\u306e\u52d5\u8a5e\u306f\u3001\u4e00\u822c\u7684\u306b\u5c06\u6765\u4e88\u6e2c\u306b\u95a2\u3059\u308b\u8a18\u8ff0\u3092\u8b58\u5225\u3059\u308b\u305f\u3081\u306b\u7528\u3044\u3089\u308c\u307e\u3059\u3002\u3053\u306e\u3088\u3046\u306a\u5c06\u6765\u4e88\u6e2c\u306b\u95a2\u3059\u308b\u8a18\u8ff0\u306b\u306f\u3001\u65e2\u77e5\u304a\u3088\u3073\u672a\u77e5\u306e\u30ea\u30b9\u30af\u3001\u4e0d\u78ba\u5b9f\u6027\u3001\u305d\u306e\u4ed6\u306e\u91cd\u8981\u306a\u8981\u56e0\u304c\u542b\u307e\u308c\u3066\u304a\u308a\u3001\u305d\u308c\u3089\u306e\u8981\u56e0\u306b\u3088\u308a\u3001CENTOGENE\u306e\u5b9f\u969b\u306e\u7d50\u679c\u3001\u696d\u7e3e\u3001\u307e\u305f\u306f\u6210\u679c\u304c\u3001\u5c06\u6765\u4e88\u6e2c\u306b\u95a2\u3059\u308b\u8a18\u8ff0\u306b\u3088\u3063\u3066\u660e\u793a\u307e\u305f\u306f\u6697\u793a\u3055\u308c\u308b\u5c06\u6765\u306e\u7d50\u679c\u3001\u696d\u7e3e\u3001\u307e\u305f\u306f\u6210\u679c\u3068\u5927\u304d\u304f\u7570\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u3053\u306e\u3088\u3046\u306a\u30ea\u30b9\u30af\u3084\u4e0d\u78ba\u5b9f\u6027\u306b\u306f\u3001\u3068\u308a\u308f\u3051\u3001\u7d4c\u6e08\u3084\u5730\u653f\u5b66\u7684\u306a\u72b6\u6cc1\u306e\u60aa\u5316\u3001\u4e16\u754c\u91d1\u878d\u5e02\u5834\u306e\u4e0d\u5b89\u5b9a\u6027\u3084\u5909\u52d5\u6027\u3001\u73fe\u884c\u304a\u3088\u3073\u63d0\u6848\u3055\u308c\u3066\u3044\u308b\u6cd5\u5f8b\u3001\u898f\u5236\u3001\u653f\u5e9c\u653f\u7b56\u306e\u5909\u66f4\u306e\u53ef\u80fd\u6027\u3001\u696d\u754c\u306b\u304a\u3051\u308b\u7af6\u4e89\u306e\u6fc0\u5316\u3084\u7d71\u5408\u306b\u3088\u308b\u5727\u529b\u3001\u7c73\u56fd\u98df\u54c1\u533b\u85ac\u54c1\u5c40\u3092\u542b\u3080\u898f\u5236\u5f53\u5c40\u306e\u627f\u8a8d\u306b\u304b\u304b\u308b\u8cbb\u7528\u3084\u4e0d\u78ba\u5b9f\u6027\u3001\u7b2c\u4e09\u8005\u3084\u5354\u529b\u30d1\u30fc\u30c8\u30ca\u30fc\u3078\u306e\u4f9d\u5b58\uff08\u6210\u9577\u3092\u7ba1\u7406\u3057\u3001\u65b0\u305f\u306a\u9867\u5ba2\u95a2\u4fc2\u3092\u7bc9\u304f\u80fd\u529b\u3092\u542b\u3080\uff09\u3001\u5e0c\u5c11\u75be\u60a3\u696d\u754c\u3078\u306e\u4f9d\u5b58\u3001\u56fd\u969b\u5c55\u958b\u3092\u7ba1\u7406\u3059\u308b\u80fd\u529b\u3001\u4e3b\u8981\u4eba\u6750\u3078\u306e\u4f9d\u5b58\u3001\u77e5\u7684\u8ca1\u7523\u4fdd\u8b77\u3078\u306e\u4f9d\u5b58\u3001\u70ba\u66ff\u30ec\u30fc\u30c8\u306e\u5f71\u97ff\u306b\u3088\u308b\u55b6\u696d\u6210\u7e3e\u306e\u5909\u52d5\u3001\u73fe\u91d1\u4f7f\u7528\u306e\u5408\u7406\u5316\u80fd\u529b\u3001\u8ffd\u52a0\u8cc7\u91d1\u8abf\u9054\u306e\u5fc5\u8981\u6027\u3001\u305d\u306e\u4ed6\u306e\u8981\u56e0\u304c\u542b\u307e\u308c\u307e\u3059\u3002\u5b9f\u969b\u306e\u696d\u7e3e\u304c\u3053\u308c\u3089\u306e\u5c06\u6765\u4e88\u6e2c\u306b\u95a2\u3059\u308b\u8a18\u8ff0\u3068\u7570\u306a\u308b\u53ef\u80fd\u6027\u306e\u3042\u308b\u30ea\u30b9\u30af\u304a\u3088\u3073\u4e0d\u78ba\u5b9f\u6027\u3001\u306a\u3089\u3073\u306bCENTOGENE\u306e\u4e8b\u696d\u5168\u822c\u306b\u95a2\u3059\u308b\u30ea\u30b9\u30af\u306e\u8a73\u7d30\u306b\u3064\u3044\u3066\u306f\u30012022\u5e743\u670830\u65e5\u306b\u7c73\u56fd\u8a3c\u5238\u53d6\u5f15\u59d4\u54e1\u4f1a\uff08\u4ee5\u4e0b\u300cSEC\u300d\uff09\u306b\u63d0\u51fa\u3055\u308c\u305fCENTOGENE\u306e\u30d5\u30a9\u30fc\u30e020-F\u304a\u3088\u3073\u305d\u306e\u5f8c\u306eSEC\u3078\u306e\u63d0\u51fa\u66f8\u985e\u306b\u8a18\u8f09\u3055\u308c\u3066\u3044\u308bCENTOGENE\u306e\u30ea\u30b9\u30af\u8981\u56e0\u3092\u53c2\u7167\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u672c\u30d7\u30ec\u30b9\u30ea\u30ea\u30fc\u30b9\u306b\u542b\u307e\u308c\u308b\u5c06\u6765\u4e88\u6e2c\u306b\u95a2\u3059\u308b\u8a18\u8ff0\u306f\u3001\u672c\u30d7\u30ec\u30b9\u30ea\u30ea\u30fc\u30b9\u306e\u65e5\u4ed8\u6642\u70b9\u306e\u3082\u306e\u3067\u3042\u308a\u3001CENTOGENE\u306f\u3001\u65b0\u305f\u306a\u60c5\u5831\u3001\u5c06\u6765\u306e\u51fa\u6765\u4e8b\u3001\u305d\u306e\u4ed6\u3044\u304b\u306a\u308b\u7406\u7531\u3067\u3042\u308c\u3001\u5c06\u6765\u4e88\u6e2c\u306b\u95a2\u3059\u308b\u8a18\u8ff0\u3092\u66f4\u65b0\u3059\u308b\u7fa9\u52d9\u3092\u4e00\u5207\u8ca0\u308f\u306a\u3044\u3053\u3068\u3092\u660e\u793a\u7684\u306b\u8868\u660e\u3057\u307e\u3059\u3002.<\/p>\n<h4 class=\"h3\">\u30e1\u30c7\u30a3\u30a2\u62c5\u5f53\u8005<\/h4>\n<h5>\u30bb\u30f3\u30c8\u30b8\u30fc\u30f3<\/h5>\n<p>\u30d9\u30f3\u30fb\u30ec\u30c3\u30b0<br \/> \u4f01\u696d\u5e83\u5831&nbsp;<br \/> <a href=\"mailto:press@centogene.com\" title=\"\u30e1\u30fc\u30eb\u3092\u66f8\u304f\">press(at)centogene(dot)com<\/a><\/p>\n<p>\u30ec\u30ca\u30fc\u30c8\u30fb\u30b7\u30e5\u30c8\u30e9\u30a4\u30d9\u30eb<br \/> \u6295\u8cc7\u5bb6\u5411\u3051\u60c5\u5831<br \/> <a href=\"mailto:investor.relations@centogene.com\" title=\"\u30e1\u30fc\u30eb\u3092\u66f8\u304f\">investor.relations(at)centogene(dot)com <\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>CENTOGENE\u3068Agios\u306f\u3001\u5e0c\u5c11\u8840\u6db2\u75be\u60a3\u306e\u5c0f\u5150\u3092\u6cbb\u7642\u3059\u308b\u305f\u3081\u306ePYRUKYND\u00ae\uff08\u30df\u30bf\u30d4\u30d0\u30c3\u30c8\uff09\u306e\u81e8\u5e8a\u958b\u767a\u306b\u304a\u3051\u308b\u63d0\u643a\u3092\u62e1\u5927<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2227","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND\u00ae (mitapivat) to Treat Children With Rare Blood Disease | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/jp\/centogene\u3068agios\u306f\u3001\u5e0c\u5c11\u8840\u6db2\u75be\u60a3\u306e\u5c0f\u5150\u3092\u6cbb\u7642\u3059\u308b\u305f\u3081\u306e\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND\u00ae (mitapivat) to Treat Children With Rare Blood Disease | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND\u00ae (mitapivat) to Treat Children With Rare Blood Disease\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/jp\/centogene\u3068agios\u306f\u3001\u5e0c\u5c11\u8840\u6db2\u75be\u60a3\u306e\u5c0f\u5150\u3092\u6cbb\u7642\u3059\u308b\u305f\u3081\u306e\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-13T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"7\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND\u00ae (mitapivat) to Treat Children With Rare Blood Disease\",\"datePublished\":\"2022-06-13T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\\\/\"},\"wordCount\":1498,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\\\/\",\"name\":\"CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND\u00ae (mitapivat) to Treat Children With Rare Blood Disease | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2022-06-13T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND\u00ae (mitapivat) to Treat Children With Rare Blood Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/jp\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE\u3068Agios\u304c\u5e0c\u5c11\u8840\u6db2\u75be\u60a3\u306e\u5c0f\u5150\u6cbb\u7642\u85acPYRUKYND\u00ae\uff08\u30df\u30bf\u30d4\u30d0\u30c3\u30c8\uff09\u306e\u81e8\u5e8a\u958b\u767a\u306b\u304a\u3051\u308b\u63d0\u643a\u3092\u62e1\u5927\uff5cCENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/jp\/centogene\u3068agios\u306f\u3001\u5e0c\u5c11\u8840\u6db2\u75be\u60a3\u306e\u5c0f\u5150\u3092\u6cbb\u7642\u3059\u308b\u305f\u3081\u306e\/","og_locale":"ja_JP","og_type":"article","og_title":"CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND\u00ae (mitapivat) to Treat Children With Rare Blood Disease | CENTOGENE","og_description":"CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND\u00ae (mitapivat) to Treat Children With Rare Blood Disease","og_url":"https:\/\/www.centogene.com\/jp\/centogene\u3068agios\u306f\u3001\u5e0c\u5c11\u8840\u6db2\u75be\u60a3\u306e\u5c0f\u5150\u3092\u6cbb\u7642\u3059\u308b\u305f\u3081\u306e\/","og_site_name":"CENTOGENE","article_published_time":"2022-06-13T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"admincg","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"7\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND\u00ae (mitapivat) to Treat Children With Rare Blood Disease","datePublished":"2022-06-13T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\/"},"wordCount":1498,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"ja","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\/","url":"https:\/\/www.centogene.com\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\/","name":"CENTOGENE\u3068Agios\u304c\u5e0c\u5c11\u8840\u6db2\u75be\u60a3\u306e\u5c0f\u5150\u6cbb\u7642\u85acPYRUKYND\u00ae\uff08\u30df\u30bf\u30d4\u30d0\u30c3\u30c8\uff09\u306e\u81e8\u5e8a\u958b\u767a\u306b\u304a\u3051\u308b\u63d0\u643a\u3092\u62e1\u5927\uff5cCENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2022-06-13T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-and-agios-expand-partnership-for-clinical-development-of-pyrukyndr-mitapivat-to-treat-children-with-rare-blood-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND\u00ae (mitapivat) to Treat Children With Rare Blood Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"\u30bb\u30f3\u30c8\u30b8\u30fc\u30f3","description":"\u7cbe\u5bc6\u533b\u7642\u306e\u6307\u91dd","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"\u30bb\u30f3\u30c8\u30b8\u30fc\u30f3","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/jp\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/jp\/wp-json\/wp\/v2\/posts\/2227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/jp\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/jp\/wp-json\/wp\/v2\/comments?post=2227"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/jp\/wp-json\/wp\/v2\/posts\/2227\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/jp\/wp-json\/wp\/v2\/media?parent=2227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/jp\/wp-json\/wp\/v2\/categories?post=2227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/jp\/wp-json\/wp\/v2\/tags?post=2227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}